Vertex (VRTX) CMO granted stock; shares withheld for taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Bozic Carmen
Role
EVP and CMO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 5,375 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,912 | $483.75 | $925K |
Holdings After Transaction:
Common Stock — 43,428 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transactions did Vertex (VRTX) report for Carmen Bozic?
Vertex reported that EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock and disposed of 1,912 shares for tax withholding. After these transactions, she directly owned 41,516 shares of Vertex common stock.
Was the Vertex (VRTX) insider transaction by Carmen Bozic a stock award?
Yes. Carmen Bozic received a 5,375-share restricted stock unit award of Vertex common stock. According to the disclosure, this award will vest in installments beginning on February 20, 2027, reflecting equity-based compensation rather than an open-market stock purchase.
When do Carmen Bozic’s new Vertex (VRTX) restricted stock units begin vesting?
The restricted stock unit award granted to Carmen Bozic begins vesting on February 20, 2027. The footnote explains that the 5,375-share award will vest in installments starting on that date, consistent with typical long-term incentive compensation structures.